Scilex Holding Company Announces Stocking of GLOPERBA® is Underway in all of the Wholesalers with which Scilex has Stocking Arrangements Throughout the U.S.

Core Viewpoint - Scilex Holding Company is launching GLOPERBA®, the first and only liquid oral formulation of colchicine for the prophylaxis of painful gout flares in adults, with stocking expected to be completed by June 12, 2024 [1][4]. Company Overview - Scilex Holding Company is headquartered in Palo Alto, California, and focuses on acquiring, developing, and commercializing non-opioid pain management products for acute and chronic pain [3][4]. - The company targets high unmet needs and large market opportunities with non-opioid therapies [2]. Product Portfolio - Scilex's commercial products include: - ZTlido® (lidocaine topical system) 1.8%, approved for neuropathic pain relief [2]. - ELYXYB®, an FDA-approved oral solution for acute migraine treatment [2]. - GLOPERBA®, launching today, indicated for the prophylaxis of painful gout flares [2][4]. - Scilex has three product candidates in development: - SP-102 (SEMDEXA™), a viscous gel for epidural injections to treat sciatica, with Phase 3 study completed [7]. - SP-103, a next-generation lidocaine topical system for chronic neck pain, recently completed Phase 2 trial [7]. - SP-104, a low-dose naltrexone for fibromyalgia, with Phase 1 trials completed [7].